Viracta Therapeutics

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. The company was founded on February 10, 1998 and is headquartered in Cardiff, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Results from Phase 1b/2 trial showed complete responses achieved and ongoing durable responses observed out to approximately 36 months across multiple EBV + lymphoma subtypes, including some of the most aggressive cancers

Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) Lymphoma

SAN DIEGO, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced the appointment of Darrel P. Cohen, M.D., Ph.D. as Chief Medical Officer (CMO), effective immediately. Dr. Cohen brings more than 25 years of global clinical research and drug development experience, having contributed to the successful regulatory submissions of multiple novel oncology therapies including SUTENT® (sunitinib), XALKORI® (crizotinib), and IBRANCE® (palbociclib). Dr. Cohen will oversee the clinical development and regulatory advancement of Nana-val in Epstein-Barr virus (EBV)-associated malignances, contribute to the strategic expansion of Viracta's pipeline, and serve on the Executive Leadership Team.

Viracta Therapeutics Appoints Darrel P. Cohen, M.D.

Early data observed from NAVAL-1 in R/R EBV+ PTCL consistent with Phase 1b/2 clinical trial Early data observed from NAVAL-1 in R/R EBV+ PTCL consistent with Phase 1b/2 clinical trial

Viracta Therapeutics' Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)

SAN DIEGO, May 31, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 3:00 p.m. EDT.

Viracta Therapeutics to Present at the Jefferies Healthcare Conference

Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV + ) lymphoma accelerating globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 anticipated in 2Q 2023

Viracta Therapeutics Reports First Quarter 2023 Financial Results and Provides Clinical Program Updates

SAN DIEGO, May 02, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Chief Medical Officer, Lisa Rojkjaer, M.D., will be leaving the company to pursue another opportunity, effective May 5, 2023. Donald Strickland, M.D., Viracta's Vice President, Clinical Development and Medical Director, and Yisrael Katz, M.D., Senior Medical Director, will continue to oversee Viracta's pivotal NAVAL-1 trial and solid tumor clinical program, respectively.

Viracta Therapeutics Announces Departure of Chief Medical Officer

SAN DIEGO, April 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 12:00 p.m. ET.

Viracta Therapeutics to Present at the Stifel 2023 Targeted Oncology Days

Pivotal NAVAL-1 study of Nana-val in Epstein-Barr virus-positive (EBV + ) lymphoma open at 70 sites globally; update on first lymphoma subtype that may advance from Stage 1 to Stage 2 expected in the first half of 2023

Viracta Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update

SAN DIEGO, March 08, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, and Lisa Rojkjaer, M.D., its Chief Medical Officer, are scheduled to participate in a virtual fireside chat at the 33rd Annual Oppenheimer Healthcare Conference on Wednesday, March 15, 2023, at 12:00 p.m. ET.

Viracta Therapeutics to Present at the 33rd Annual Oppenheimer Healthcare Conference

SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that Mark Rothera, its President and Chief Executive Officer, is scheduled to present at the virtual 2023 SVB Securities Global Biopharma Conference on Tuesday, February 14, 2023, at 1:00 p.m. ET.

Viracta Therapeutics to Present at the 2023 SVB Securities Global Biopharma Conference

Sixth orphan drug designation for Nana-val globally; second granted by the European Commission Sixth orphan drug designation for Nana-val globally; second granted by the European Commission

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission to Nana-val for the Treatment of Diffuse Large B-cell Lymphoma

Partial response (PR) observed in third dose level of the Phase 1b dose escalation study of Nana-val in EBV + recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC); enrollment into forth dose level is ongoing

Viracta Therapeutics Announces First Clinical Response in Epstein-Barr Virus-Positive (EBV+) Solid Tumor Setting and Outlines Key 2023 Clinical Objectives

Data from first two dose levels of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma support continued dose escalation to determine the optimal recommended Phase 2 dose Data from first two dose levels of Nana-val in patients with EBV+ recurrent/metastatic nasopharyngeal carcinoma support continued dose escalation to determine the optimal recommended Phase 2 dose

Viracta Therapeutics Announces Preliminary Dose-Ranging Data from the Phase 1b/2 Trial of Nana-val in Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors at the ESMO Immuno-Oncology Congress

Pivotal NAVAL-1 trial of Nana-val in Epstein-Barr virus-positive (EBV + ) lymphoma open for enrollment at more than 50 sites worldwide; update on the first indication that may advance from Stage 1 to Stage 2 now anticipated in the first half of 2023

Viracta Therapeutics Reports Third Quarter 2022 Financial Results and Provides Updates on Clinical Programs

Viracta Therapeutics' Board of Directors appoints Mark Rothera as President and Chief Executive Officer Founding President and CEO Ivor Royston, M.D., will continue to serve as a Member of Viracta's Board of Directors SAN DIEGO , Sept.

Viracta Therapeutics Announces Chief Executive Officer Leadership Succession to Drive the Next Phase of the Company's Strategic Development and Growth

The consensus price target hints at a 334.8% upside potential for Sunesis (VIRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Sunesis (VIRX) Have the Potential to Rally 335% as Wall Street Analysts Expect?

Viracta (VIRX) receives Orphan Drug designation from the European Commission for its lead candidate Nana-val for treating peripheral T-cell lymphoma. Stock up.

Viracta (VIRX) Up on Orphan Drug Tag for Peripheral Lymphoma

First orphan drug designation granted for Nana-val by the European Commission; fifth globally SAN DIEGO , Sept. 7, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the European Commission has granted an orphan drug designation (ODD) to nanatinostat and valganciclovir (Nana-val), the company's all-oral combination product candidate, for the treatment of peripheral T-cell lymphoma (PTCL).

Viracta Therapeutics Announces Orphan Drug Designation Granted by the European Commission for Nana-val for the Treatment of Peripheral T-cell Lymphoma

SAN DIEGO , Aug. 16, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the International Association for Research on Epstein-Barr Virus and Associated Disease (EBV Association) has elected Viracta's Chief Scientific Officer, Ayman Elguindy, Ph.D., to its Governing Board.

Viracta Therapeutics Chief Scientific Officer, Dr. Ayman Elguindy, Elected to the Governing Board of the International Association for Research on Epstein-Barr Virus and Associated Diseases

SAN DIEGO , Aug. 11, 2022 /PRNewswire/ -- Viracta  Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to its Board of Directors.

Viracta Therapeutics Appoints Jane Chung, R.Ph., to its Board of Directors

Continued progress of NAVAL-1, the pivotal trial of Nana-val for the treatment of Epstein-Barr virus-positive (EBV+) lymphoma; update on the initial cohort(s) expanding into Stage 2 is anticipated in the fourth quarter of 2022 Advanced the Phase 1b/2 trial of Nana-val in EBV+ solid tumors into the second dose escalation cohort; preliminary safety and efficacy data are anticipated in the fourth quarter of 2022 Cash, cash equivalents and investments of $83.1 million as of June 30, 2022, provides projected runway into mid-2024 SAN DIEGO , Aug. 9, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today reported financial results for the second quarter of 2022 and provided an update on recent corporate developments. "We are pleased with our corporate progress in the first half of 2022, having advanced both of our Nana-val clinical trials towards important milestones anticipated later this year, while maintaining a strong cash position that provides a projected runway into the middle of 2024," said Ivor Royston, M.D.

Viracta Therapeutics Reports Second Quarter 2022 Financial Results and Recent Updates

Viracta Therapeutics' (VIRX) Nana-val is being evaluated in multiple clinical studies in various subtypes of EBV-associated cancers.

Here's Why Viracta Therapeutics (VIRX) is Up So Far This Year

Assertio Therapeutics Inc

Chinook Therapeutics

Soleno Therapeutics

It is expected that innovation will continue to drive growth in the Medical-Drugs industry in 2022. KDNY, ASRT, VIRX, SLNO may prove to be good additions to one's portfolio.

4 Small Stocks to Bet on in an Upbeat Drugs Industry

SAN DIEGO , June 13, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that its President and Chief Executive Officer, Ivor Royston, M.D., is being presented with the Science History Institute's Biotechnology Heritage Award.

Viracta Therapeutics President and Chief Executive Officer Dr. Ivor Royston Receives the Science History Institute's Biotechnology Heritage Award

Trial has advanced to the second dose escalation cohort with no dose-limiting toxicities observed to-date SAN DIEGO , June 2, 2022 /PRNewswire/ -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that the Safety Monitoring Committee for the ongoing Phase 1b/2 study of Nana-val in patients with EBV+ solid tumors (VT3996-301) has reviewed safety data from the first dose cohort of patients with recurrent or metastatic nasopharyngeal cancer (RM-NPC) and has approved advancing to the next dose level. Newly enrolled patients will enter the trial's second cohort and receive nanatinostat 30 mg orally, 4 days per week, in combination with valganciclovir 900 mg orally daily.

Viracta Therapeutics Provides an Update on the Phase 1b/2 Trial of Nana-val in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and Announces Upcoming Poster Presentation at the ASCO Annual Meeting

News for Viracta Therapeutics Stock (VIRX)